Abbott has received CE mark to market its new transcatheter aortic valve implantation (TAVI) system, Navitor, in Europe to treat severe aortic stenosis patients with high or extreme surgical risk.
A minimally invasive device, Navitor has a fabric cuff called NaviSeal that acts with the cardiac cycle to lower or prevent paravalvular leak (PVL).
PVL is a complication that results from TAVI procedures and causes blood backflow around the valve frame.
The latest device is a self-expanding TAVI system with intra-annular leaflets and large frame cells. It could offer access to vital coronary arteries to aid procedures for coronary artery disease treatment in the future.
